Abstract
Scope:
Although sarcopenia is mainly caused by aging, sarcopenia due to obesity has become an emerging issue given the increase in obesity among people of various ages. There are studies on obesity or sarcopenia, our understanding of obesity-mediated sarcopenia is insufficient. Luteolin has exhibited anti-obesity effects, but no studies have investigated the luteolin effects on anti-sarcopenia. We therefore investigated the effects of luteolin on obese sarcopenia in mice with HFD-induced obesity.
Methods and results:
To evaluate its inhibitory efficacy against obese sarcopenia, 5-week-old mice were fed a HFD supplemented with luteolin for 20 weeks. Luteolin exerted suppressive effects on obesity, inflammation, and protein degradation in the HFD-fed obese mice. It also inhibited lipid infiltration into the muscle and decreased p38 activity and the mRNA expression of inflammatory factors, including TNF-α, Tlr2, Tlr4, MCP1, and MMP2, in the muscle. The suppression of muscle inflammation by luteolin led to the inhibition of myostatin, FoxO, atrogin, and MuRF expression. These effects of luteolin affected inhibition of protein degradation and improvement of muscle function.
Conclusion:
Here, we demonstrate that luteolin's anti-obesity and anti-inflammatory functionality affect inhibition of muscle protein degradation, and consequently, these interactions by luteolin exerts a protective effect against obese sarcopenia. This article is protected by copyright. All rights reserved.
Full text
